BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT

The study will be conducted in three phases: 1) Screening Phase, 2) Double-blind Randomized Phase (1 year), and 3) Unblinded Phase (2 years). Patients scheduled for implantation of an Astra/Azure pacemaker, or those who already have one implanted, who also have hypertension, may be screened for inclusion into this study. Subjects meeting randomization eligibility criteria will have the investigational AVIM Therapy RAMware downloaded into the Astra/Azure pacemaker and be randomized 1:1 to either have AVIM therapy turned ON or turned OFF. All subjects will continue to receive antihypertensive drug therapy.

Inclusion criteria

• Patient has or is indicated for a dual-chamber pacemaker. Visit 1 can be performed within 30 days prior to a planned implant of a Medtronic Astra/Azure dual-chamber pacemaker system or at any time thereafter
• On a stable antihypertension treatment regimen with at least 1 class of antihypertensive drug
• Office SBP ≥135 mmHg and <180 mmHg
• Average 24-Hour aSBP ≥130 mmHg and <170 mmHg

Exclusion criteria

• LVEF <50%
• NYHA Class III-IV
• History of cerebrovascular accident (CVA) or transient ischemic attack (TIA) within 6 months
• Myocardial infarction (MI) within 3 months
• Prior percutaneous or surgical coronary, carotid, or endovascular intervention within 3 months
• Permanent atrial fibrillation
• Mitral valve regurgitation greater than or equal to grade 3
• Aortic stenosis with a valve area less than 1.5 cm2
• Has an active or prior device-based anti-hypertensive treatment (e.g., renal denervation procedure, baroreflex activation therapy)
• Has an existing active cardiac device or neurostimulator other than the recent Astra/Azure pacemaker implant